NDAORALTABLETPriority Review
Approved
Nov 1959
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISORDIL (isosorbide dinitrate) is an oral nitrate vasodilator approved in 1959 for heart failure management. It relaxes vascular smooth muscle to reduce preload and afterload on the heart, with effects on both peripheral and coronary arteries. The drug is taken by patients with chronic heart failure to reduce anginal symptoms and improve exercise tolerance.
LOE Approaching
As lifecycle approaches end-of-exclusivity, ISORDIL brand team is likely consolidating resources with reduced headcount and transitioning focus to generic competition management and potential line extensions.
Mechanism of Action
Pharmacologic Class:
Nitrate Vasodilator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ISORDIL offers limited career growth potential due to its approaching loss-of-exclusivity, minimal commercial spending, and mature product lifecycle dominated by generic competition. Roles on this product are primarily focused on defending market share and managing decline rather than driving growth or innovation.
Product ManagerBrand Manager
Worked on ISORDIL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.